Tag: regenerative medicine
In mouse study, nerve pain drug gabapentin promotes regeneration of neural circuits
Long-term treatment with gabapentin, a commonly prescribed drug for nerve pain, could help restore upper limb function after a spinal cord injury, new research in mice suggests.
In the study, mice treated with gabapentin regained roughly 60 percent of forelimb function in a skilled walking test, compared to restoration of approximately 30 percent of forelimb function in mice that received a placebo.
Japanese Researchers Will Use Stem Cells to Treat Spinal Cord Injuries in Groundbreaking Clinical...
There could a new form of treatment in Japan for spinal cord injuries if a newly-approved clinical trial hits the mark.
On Monday, a special committee of the Ministry of Health, Labor and Welfare in Japan approved a clinical research program at Tokyo’s Keio University to use induced pluripotent stem (iPS) cells to treat spinal cord injuries. According to the Nikkei Asian Review, this is a groundbreaking first-of-its-kind study. The clinical trial is expected to begin this summer.
Modern medicine has still not managed to crack the problem of spinal cord injuries that result in significant paralysis or loss of functional status.
There are numerous factors that influence the inability to restore movement or autonomous bodily control to these patients. A prominent example of these is the inability to cultivate new neurons that make up and power the spinal cord.
However, some researchers have claimed that they have successfully induced ‘generic’ human stem cells to differentiate into stem cells that apply more specifically to the spine.
Why build something from the ground up when one can just renovate an already existing structure? Essentially, that’s what researchers from the University of Washington School of Medicine in St. Louis had in mind when they developed a method for transforming adult human skin cells into motor neurons in a lab. They published their work in the journal Cell Stem Cell.
Lengthy study finds that implanted neural stem cells grow slow and steady, and success needs to be measured accordingly
More than one-and-a-half years after implantation, researchers at University of California San Diego School of Medicine and the San Diego Veterans Administration Medical Center report that human neural stem cells (NSCs) grafted into spinal cord injuries in laboratory rats displayed continued growth and maturity, with functional recovery beginning one year after grafting.
For a soldier who suffered a spinal cord injury on the battlefield, the promise of regenerative medicine is to fully repair the resulting limb paralysis. But that hope is still years from reality.
Not only powerful, but efficient. Studying diseases in lab-created tissue may help reduce the price tag — now roughly $1.8 billion — for bringing a new drug to market, which is one of the reasons Ashton received a National Science Foundation CAREER Award for advancing tissue engineering of the human spinal cord. During the project’s five-year funding period, his lab in the Wisconsin Institute for Discovery will fine-tune the technology for growing a neural tube, the developmental predecessor of the spinal cord, from scratch.
A UCLA professor is working to develop a treatment for spinal cord injuries, which are currently incurable.
Stephanie Seidlits, assistant professor of bioengineering, will attempt to use biomaterial made out of hyaluronic acid – a long chain of sugars in the body – to create a treatment that can be injected into spinal cords. Seidlits will conduct the research with students using a $500,000 grant she won March 1.
The prestigious CAREER award, granted by the National Science Foundation, aims to support scholars who effectively integrate research with education.
Early clinical trial results announced offer new hope in regenerative medicine
A new therapy to treat spinal cord injuries in people who have lost all motor and sensory function below the injury site shows additional motor function improvement at 6-months and 9-months following treatment with 10 million AST-OPC1. The positive efficacy results from an ongoing research study were announced on Jan. 24 in a conference held by Asterias Biotherapeutics, Inc., the biotechnology company that manufactures AST-OPC1.
Newswise — DALLAS – Oct. 11, 2016 – UT Southwestern Medical Center researchers successfully boosted the regeneration of mature nerve cells in the spinal cords of adult mammals – an achievement that could one day translate into improved therapies for patients with spinal cord injuries.
“This research lays the groundwork for regenerative medicine for spinal cord injuries. We have uncovered critical molecular and cellular checkpoints in a pathway involved in the regeneration process that may be manipulated to boost nerve cell regeneration after a spinal injury,” said senior author Dr. Chun-Li Zhang, Associate Professor of Molecular Biology at UT Southwestern.
Spinal cord injuries are mostly caused by trauma, often incurred in road traffic or sporting incidents, often with devastating and irreversible consequences, and unfortunately having a relatively high prevalence (250,000 patients in the USA; 80% of cases are male). One currently explored approach to restoring function after spinal cord injury is the transplantation of olfactory ensheathing cells (OECs) into the damaged area. The hope is that these will encourage the repair of damaged neurons, but does it work? And if so, how can it be optimized?